Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.
about
Recombinant human activated protein C for severe sepsis in neonatesRecombinant human activated protein C for severe sepsis in neonatesT-cell-mediated immunity and the role of TRAIL in sepsis-induced immunosuppressionEfficacy and effectiveness of recombinant human activated protein C in severe sepsis of adultsDrotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysisPractical aspects of treatment with drotrecogin alfa (activated)Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?Immunogenetics of severe respiratory infections: models for the development of new therapeutic strategies.Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma.Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.Drotrecogin alfa (activated) in the treatment of severe sepsis.Management of sepsis in the critically ill patient: key aspects.Cost effectiveness of intensive care in a low resource setting: A prospective cohort of medical critically ill patients.Simplified pharmacoeconomics of critical care and severe sepsis.Drotrecogin alpha (activated): the treatment for severe sepsis?Why activated protein C was not successful in severe sepsis and septic shock: are we still tilting at windmills?Monitoring a high-cost drug in critical care units.
P2860
Q24200439-673235C9-7194-409A-85DC-6F780C871A16Q24246064-EA1F60B8-7639-4A29-8AB3-898AE4DD820EQ26823892-1307304B-4BD2-42A4-BB8E-1958EFA20743Q28743919-22D8ED8F-7516-429A-8EAA-17FE897C8BD6Q33288889-5023763B-0B99-4048-BD88-51A84FD82FE7Q33378616-42923703-D192-4E0E-9679-A91AED4859DAQ34568205-10CAE937-F080-49AA-90DC-46A271B64A0CQ35908186-6B2211C7-D7E7-4632-9543-83D887FE3F91Q36279653-742BADB4-9E73-4CAD-BE6F-89F74D963600Q36349735-20A572F3-3B23-485E-8B02-E2DA9B52137FQ36468104-37105CD3-A9F1-47D9-B0BE-D97E1A6CACC1Q36607385-968B5EF7-D696-4C50-9480-ACEA2503669AQ36613922-485D2F79-0007-4E4E-9831-DF96338D0B9EQ36844825-D21951CC-E4A4-494A-860C-4976BEC9CEFCQ36951502-88C97E38-66ED-4F80-A8CA-B0DBC4A2995DQ36981698-7853C304-FB5F-4F22-8CA5-B095E2A283F3Q39370623-894A6F84-CC35-40DC-9F80-347096461D9BQ45792672-93D1C702-7395-4EC5-97E4-98539DF6997F
P2860
Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Clinical effectiveness and cos ...... eview and economic evaluation.
@ast
Clinical effectiveness and cos ...... eview and economic evaluation.
@en
type
label
Clinical effectiveness and cos ...... eview and economic evaluation.
@ast
Clinical effectiveness and cos ...... eview and economic evaluation.
@en
prefLabel
Clinical effectiveness and cos ...... eview and economic evaluation.
@ast
Clinical effectiveness and cos ...... eview and economic evaluation.
@en
P2093
P356
P1476
Clinical effectiveness and cos ...... review and economic evaluation
@en
P2093
P304
1-126, iii-iv
P356
10.3310/HTA9110
P577
2005-03-01T00:00:00Z